Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study-Reference-Cited by-同舟云学术

Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study

Published:2022-04 Issue: Volume:303 Page:123-130
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Thase Michael E.,Jacobsen Paula L.,Hanson Elizabeth,Xu Rengyi,Tolkoff Max,Murthy Naga Venkatesha

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference15 articles.

1. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder;Alvarez;Int. J. Neuropsychopharmacol.,2012

2. American Psychiatric Association. 2010. Practice guideline for the treatment of patients with major depressive disorder. 3rd edition. October 2010. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf (accessed February 19, 2021).

3. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms;Baldwin;J. Affect. Disord.,2016

4. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder;Bang-Andersen;J. Med. Chem.,2011

5. Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and drug administration;Borges;J. Clin. Psychiatry,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder;Expert Review of Neurotherapeutics;2024-03-27

2. The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature;Journal of Clinical Medicine;2024-01-17

3. Medications for Depression: Monoamine Enhancers and Esketamine (Antidepressants);Tasman’s Psychiatry;2024

4. Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study;BMC Psychiatry;2023-12-13

5. We Are Their Hope: Addressing Mental Health Barriers Through Advocacy;Journal of Psychosocial Nursing and Mental Health Services;2023-09